Celcuity Rises as Investors Focus on Near-Term FDA Catalyst for Gedatolisib

Celcuity (CELC) is up 6.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is growing investor positioning ahead of the company’s July 17, 2026 FDA decision date for gedatolisib in HR+/HER2- PIK3CA wild-type advanced breast cancer. Continued interest may also reflect Phase 3 results released this year and signs that Celcuity has been preparing financially and operationally for a potential commercial launch.

Details:

In January 2026, the FDA accepted Celcuity’s new drug application for gedatolisib and granted Priority Review, setting a July 17, 2026 action date.

Celcuity said its Phase 3 VIKTORIA-1 program achieved its primary endpoint in the PIK3CA mutant cohort, adding to earlier positive data in the wild-type setting and helping reinforce the broader gedatolisib story.

Management has said it is on track to launch gedatolisib commercially in the third quarter of 2026 if approval is received, which can support speculative buying ahead of a binary regulatory event.

In June, the company also raised a large convertible notes financing and said proceeds would support debt repayment, working capital, launch, and commercialization activities, which may have eased balance-sheet concerns.

Sources:

Celcuity Investor Relations, SEC, StockAnalysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CELC Insider Trading Activity

$CELC insiders have traded $CELC stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $CELC stock by insiders over the last 6 months:

DAVID DALVEY has made 0 purchases and 2 sales selling 45,000 shares for an estimated $5,917,538.
RICHARD E BULLER has made 0 purchases and 6 sales selling 9,000 shares for an estimated $1,264,180.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive CELC Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$CELC Hedge Fund Activity

We have seen 141 institutional investors add shares of $CELC stock to their portfolio, and 93 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

RTW INVESTMENTS, LP added 2,489,461 shares (+452.5%) to their portfolio in Q1 2026, for an estimated $284,147,078
NEA MANAGEMENT COMPANY, LLC removed 1,250,000 shares (-35.4%) from their portfolio in Q1 2026, for an estimated $142,675,000
TORONTO DOMINION BANK added 882,758 shares (+inf%) to their portfolio in Q1 2026, for an estimated $100,757,998
SOLEUS CAPITAL MANAGEMENT, L.P. removed 523,880 shares (-29.0%) from their portfolio in Q1 2026, for an estimated $59,795,663
HOLOCENE ADVISORS, LP removed 325,361 shares (-46.8%) from their portfolio in Q1 2026, for an estimated $37,136,704
SIO CAPITAL MANAGEMENT, LLC removed 283,224 shares (-59.4%) from their portfolio in Q1 2026, for an estimated $32,327,187
POINT72 ASSET MANAGEMENT, L.P. added 280,324 shares (+inf%) to their portfolio in Q1 2026, for an estimated $31,996,181

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$CELC Price Targets

Multiple analysts have issued price targets for $CELC recently. We have seen 7 analysts offer price targets for $CELC in the last 6 months, with a median target of $160.0.

Here are some recent targets:

Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $145.0 on 06/03/2026
Eva Fortea Verdejo from Wells Fargo set a target price of $166.0 on 06/03/2026
Alexander Nowak from Craig-Hallum set a target price of $171.0 on 06/03/2026
Gil Blum from Needham set a target price of $157.0 on 05/15/2026
Brad Canino from Guggenheim set a target price of $165.0 on 05/04/2026
Silvan Turkcan from Citizens set a target price of $160.0 on 05/04/2026
Stephen Willey from Stifel set a target price of $125.0 on 03/26/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.